C4orf33

Across TCGA pan-cancer cohorts, C4orf33 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C4orf33 data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher C4orf33 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C4orf33 expression acts as an unfavorable survival marker.

HNSC, KIRC, and LUAD are the cancer types where C4orf33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.231	0.727	<.001	36	view →
KIRC	OS	Median	All	0.141	0.655	.026	12	view →
LUAD	OS	Median	All	0.338	0.834	.004	12	view →
UCEC	OS	Median	IV	0.133	0.754	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C4orf33–HNSC (OS)

Open the HNSC breakdown →